CVS Caremark Reports Record Second Quarter Results

Tuesday, August 5, 2014

WOONSOCKET, R.I., Aug. 5, 2014 /PRNewswire/ --

Second Quarter Year-over-year Highlights:

  • Net revenues increased 10.7% to approximately $34.6 billion
  • Operating profit increased 11.9% to approximately $2.2 billion
  • Adjusted EPS increased 16.5% to $1.13, while GAAP diluted EPS from continuing operations increased 16.7% to $1.06

Year-to-date Highlights:

  • Generated free cash flow of $2.2 billion
  • Cash flow from operations of $3.1 billion

2014 Guidance:

  • Full-year Adjusted EPS range raised and narrowed to $4.43 to $4.51, up from $4.36 to $4.50
  • GAAP diluted EPS from continuing operations range raised and narrowed to $4.16 to $4.24, up from $4.09 to $4.23
  • Provided third quarter Adjusted EPS guidance of $1.11 to $1.14 and GAAP diluted EPS from continuing operations guidance of $1.04 to $1.07
  • Full year free cash flow range confirmed at $5.5 to $5.8 billion; cash flow from operations raised to $7.2 to $7.5 billion, up from $7.0 to $7.3 billion

CVS Caremark Corporation (NYSE: CVS) today announced operating results for the three months ended June30, 2014.

Revenues

Net revenues for the three months ended June30, 2014, increased 10.7%, or approximately $3.4 billion, to $34.6 billion compared to the three months ended June30, 2013.

Revenues in the Pharmacy Services Segment increased 16.2%, or $3.0 billion, to $21.8 billion in the three months ended June30, 2014. The increase was driven by net new business, growth in specialty pharmacy including the acquisition of Coram and the impact of Specialty Connect, drug inflation and product mix, partially offset by an increase in generic dispensing. Pharmacy network claims processed during the three months ended June30, 2014 increased 2.2% to 210.4 million compared to 205.9 million in the prior year. The increase in the pharmacy network claim volume was primarily due to net new business, partially offset by a decrease in Medicare Part D claims. Mail choice claims processed during the three months ended June30, 2014 decreased 1.0% to 20.5 million, compared to 20.7 million in the prior year. The decrease in mail choice claims was driven by a decline in traditional mail volumes, which was partially offset by growth in our Maintenance Choice program.

Revenues in the Retail Pharmacy Segment increased 4.5%, or $732 million, to $16.9 billion in the three months ended June 30, 2014. Same store sales increased 3.3% versus the second quarter of last year, with pharmacy same store sales up 5.0% and front store same store sales down 0.4%. Pharmacy same store prescription volumes rose 3.9% on a 30-day equivalent basis. Front store same store sales were positively impacted by approximately 80 basis points from the shift of the Easter holiday from March in 2013 to April in 2014. Front store same store sales were negatively impacted by softer customer traffic, partially offset by an increase in basket size. In addition, front store same store sales would have been approximately 110 basis points higher if tobacco and the estimated associated basket sales were excluded. Pharmacy same store sales were negatively impacted by approximately 160 basis points from recent generic drug introductions and by approximately 130 basis points from the implementation of Specialty Connect. The implementation of Specialty Connect had a greater effect on revenues than prescription volumes due to the higher dollar value of specialty products.

Specialty Connect integrates the Company's mail and retail capabilities, providing members with the choice to bring their specialty prescriptions to any CVS/pharmacy location. Whether submitted through our mail order pharmacy or at CVS/pharmacy, all prescriptions are filled through the Company's specialty mail order pharmacies, so all revenue from this specialty prescription services program is recorded within the Pharmacy Services Segment. Members then can choose to pick up their medication at their local CVS/pharmacy or have it sent to their home through the mail.

For the three months ended June30, 2014, the generic dispensing rate increased approximately 180 basis points in the Pharmacy Services Segment, to 82.4%, and approximately 160 basis points in the Retail Pharmacy Segment, to 83.5%, compared to the prior year.

Net Income

Net income for the three months ended June30, 2014, increased 10.9%, or approximately $122 million, to $1.2 billion, compared with approximately $1.1 billion during the three months ended June30, 2013. The Pharmacy Services and Retail Pharmacy segments both benefited from the impact of increased generic drugs dispensed and, consistent with our guidance, from the State of California's finalization of Medicaid reimbursement rates relative to our historic rate estimates. The Pharmacy Services Segment was positively impacted by growth in specialty pharmacy and favorable purchasing economics. The Retail Pharmacy Segment was positively impacted by increased sales and an improved margin rate, partially offset by incremental store operating costs associated with operating more stores. Adjusted earnings per share (Adjusted EPS) for the three months ended June30, 2014 and 2013, was $1.13 and $0.97, respectively, an increase of 16.5%. Adjusted EPS in the three months ended June 30, 2014 excludes $133 million and $124 million in 2014 and 2013, respectively, of intangible asset amortization related to acquisition activity. GAAP earnings per diluted share for the three months ended June30, 2014 and 2013, was $1.06 and $0.91, respectively, an increase of 16.7%.

President and Chief Executive Officer LarryMerlo stated, "I'm extremely pleased with our strong performance this quarter. With Adjusted EPS increasing 16.5%, we came in two cents above the high end of our expectations. This was fueled by solid results across the enterprise, as both the PBM and retail businesses exceeded revenue expectations while delivering strong gross margins. Operating profit in the PBM increased 30%, exceeding expectations, while operating profit in the retail business grew 6.5%, at the high end of our expectations." Mr. Merlo continued, "Additionally, we have generated significant free cash flow through the first half of this year. Between dividends and share repurchases, we have returned $2.6 billion to our shareholders year-to-date, and remain on track to achieve our goal of returning more than $5 billion in 2014."

Guidance

The Company raised and narrowed its earnings guidance range for the full year 2014. The Company now expects to deliver Adjusted EPS of $4.43 to $4.51, up from $4.36 to $4.50. GAAP diluted EPS from continuing operations was raised to $4.16 to $4.24, up from $4.09 to $4.23.The Company continues to expect to deliver 2014 free cash flow of $5.5 billion to $5.8 billion, while the 2014 cash flow from operations range was raised to $7.2 billion to $7.5 billion, up from $7.0 to $7.3 billion. The Company expects to deliver Adjusted EPS of $1.11 to $1.14 and GAAP diluted EPS from continuing operations of $1.04 to $1.07 in the third quarter of 2014.

Real Estate Program

During the three months ended June30, 2014, the Company opened 34 new retail drugstores and closed four retail drugstores. In addition, the Company relocated eight retail drugstores. As of June30, 2014, the Company operated 7,859 locations in 47 states, the District of Columbia, Puerto Rico and Brazil. These locations included 7,705 retail drugstores, 860 health care clinics, 17 onsite pharmacies, 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies, four mail service dispensing pharmacies, and 84 branches and six centers of excellence for infusion and enteral services.

Teleconference and Webcast

The Company will be holding a conference call today for the investment community at 8:30 am (EDT) to discuss its quarterly results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Caremark website at http://info.cvscaremark.com/investors. This webcast will be archived and available on the website for a one-year period following the conference call.

About the Company

CVS Caremark is dedicated to helping people on their path to better health as the largest integrated pharmacy company in the United States. Through the Company's more than 7,700 retail pharmacystores; its leading pharmacy benefit manager serving nearly 65 million plan members; and its retail health clinic system, the largest in the nation with more than 860 MinuteCliniclocations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare PartD Prescription Drug Plans. As a pharmacy innovation company, CVS Caremark continually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisorprogram that helps people with chronic diseases such as diabetes obtain and stay on their medications. Find more information about CVS Caremark at http://info.cvscaremark.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section in our Annual Report on Form10-K for the year ended December31, 2013 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.

 

 

CVS CAREMARK CORPORATION

Condensed Consolidated Statements of Income

(Unaudited)

         
         
   

ThreeMonthsEnded

June30,

 

Six MonthsEnded

June30,

Inmillions,exceptpershareamounts

 

2014

   

2013

   

2014

   

2013

 
                         

Net revenues

 

$

34,602

   

$

31,248

   

$

67,291

   

$

61,999

 

Cost of revenues

 

28,278

   

25,407

   

55,025

   

50,581

 

Gross profit

 

6,324

   

5,841

   

12,266

   

11,418

 

Operating expenses

 

4,116

   

3,869

   

8,034

   

7,752

 

Operating profit

 

2,208

   

1,972

   

4,232

   

3,666

 

Interest expense, net

 

158

   

126

   

316

   

252

 

Income before income tax provision

 

2,050

   

1,846

   

3,916

   

3,414

 

Income tax provision

 

804

   

721

   

1,541

   

1,335

 

Income from continuing operations

 

1,246

   

1,125

   

2,375

   

2,079

 

Loss from discontinued operations, net of tax

 

 

   

(1)

   

 

   

(1)

 

Net income

 

$

1,246

   

$

1,124

   

$

2,375

   

$

2,078

 
                         

Basic earnings per share:

                       

Income from continuing operations

 

$

1.07

   

$

0.92

   

$

2.03

   

$

1.69

 

Loss from discontinued operations

 

$

 

   

$

 

   

$

 

   

$

 

 

Net income

 

$

1.07

   

$

0.92

   

$

2.03

   

$

1.69

 

Weighted average basic shares outstanding

 

1,165

   

1,227

   

1,172

   

1,230

 
                         

Diluted earnings per share:

                       

Income from continuing operations

 

$

1.06

   

$

0.91

   

$

2.01

   

$

1.68

 

Loss from discontinued operations

 

$

 

   

$

 

   

$

 

   

$

 

 

Net income

 

$

1.06

   

$

0.91

   

$

2.01

   

$

1.68

 

Weighted average diluted shares outstanding

 

1,174

   

1,236

   

1,182

   

1,238

 
                         

Dividends declared per share

 

$

0.275

   

$

0.225

   

$

0.550

   

$

0.450

 

 

 

CVS CAREMARK CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)

         
         
   

June 30,

 

December 31,

Inmillions,exceptpershareamounts

 

2014

   

2013

 

Assets:

           

Cash and cash equivalents

 

$

1,612

   

$

4,089

 

Short-term investments

 

100

   

88

 

Accounts receivable, net

 

9,533

   

8,729

 

Inventories

 

11,360

   

11,045

 

Deferred income taxes

 

979

   

902

 

Other current assets

 

554

   

472

 

Total current assets

 

24,138

   

25,325

 

Property and equipment, net

 

8,820

   

8,615

 

Goodwill

 

28,126

   

26,542

 

Intangible assets, net

 

9,906

   

9,529

 

Other assets

 

1,603

   

1,515

 

Total assets

 

$

72,593

   

$

71,526

 
             

Liabilities:

           

Accounts payable

 

$

5,780

   

$

5,548

 

Claims and discounts payable

 

4,918

   

4,548

 

Accrued expenses

 

4,812

   

4,768

 

Current portion of long-term debt

 

1,119

   

561

 

Total current liabilities

 

16,629

   

15,425

 

Long-term debt

 

12,252

   

12,841

 

Deferred income taxes

 

4,091

   

3,901

 

Other long-term liabilities

 

1,489

   

1,421

 

Commitments and contingencies

 

 

   

 

 
             

Shareholders' equity:

           

CVS Caremark shareholders' equity:

           

Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding

 

 

   

 

 

Common stock, par value $0.01: 3,200 shares authorized; 1,688 shares issued and 1,160

           

shares outstanding at June 30, 2014 and 1,680 shares issued and 1,180 shares

           

outstanding at December31, 2013

 

17

   

17

 

Treasury stock, at cost: 527 shares at June30, 2014 and 500 shares at December31,

           

2013

 

(22,131)

   

(20,169)

 

Shares held in trust: 1 share at June30, 2014 and December31, 2013

 

(31)

   

(31)

 

Capital surplus

 

30,186

   

29,777

 

Retained earnings

 

30,221

   

28,493

 

Accumulated other comprehensive income (loss)

 

(132)

   

(149)

 

Total CVS Caremark shareholders' equity

 

38,130

   

37,938

 

Noncontrolling interest

 

2

   

 

 

Total shareholders' equity

 

38,132

   

37,938

 

Total liabilities and shareholders' equity

 

$

72,593

   

$

71,526

 

 

 

CVS CAREMARK CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)

     
     
   

Six MonthsEnded

June30,

Inmillions

 

2014

   

2013

 

Cash flows from operating activities:

           

Cash receipts from customers

 

$

62,932

   

$

56,446

 

Cash paid for inventory and prescriptions dispensed by retail network pharmacies

 

(50,268)

   

(44,657)

 

Cash paid to other suppliers and employees

 

(7,787)

   

(7,452)

 

Interest received

 

6

   

2

 

Interest paid

 

(331)

   

(267)

 

Income taxes paid

 

(1,483)

   

(1,530)

 

Net cash provided by operating activities

 

3,069

   

2,542

 
             

Cash flows from investing activities:

           

Purchases of property and equipment

 

(891)

   

(804)

 

Proceeds from sale-leaseback transactions

 

5

   

 

 

Proceeds from sale of property and equipment

 

7

   

11

 

Acquisitions (net of cash acquired) and other investments

 

(2,248)

   

(300)

 

Purchase of available-for-sale investments

 

(161)

   

 

 

Sale or maturity of available-for-sale investments

 

103

   

 

 

Net cash used in investing activities

 

(3,185)

   

(1,093)

 
             

Cash flows from financing activities:

           

Decrease in short-term debt

 

 

   

(690)

 

Repayments of long-term debt

 

(41)

   

 

 

Dividends paid

 

(647)

   

(553)

 

Proceeds from exercise of stock options

 

266

   

309

 

Excess tax benefits from stock-based compensation

 

65

   

34

 

Repurchase of common stock

 

(2,001)

   

(748)

 

Net cash used in financing activities

 

(2,358)

   

(1,648)

 

Effect of exchange rates on cash

 

(3)

   

(2)

 

Net decrease in cash and cash equivalents

 

(2,477)

   

(201)

 

Cash and cash equivalents at the beginning of the period

 

4,089

   

1,375

 

Cash and cash equivalents at the end of the period

 

$

1,612

   

$

1,174

 
             

Reconciliation of net income to net cash provided by operating activities:

           

Net income

 

$

2,375

   

$

2,078

 

Adjustments required to reconcile net income to net cash provided by operating activities:

           

Depreciation and amortization

 

965

   

951

 

Stock-based compensation

 

77

   

66

 

Deferred income taxes and other non-cash items

 

44

   

82

 

Change in operating assets and liabilities, net of effects of acquisitions:

           

Accounts receivable, net

 

(584)

   

(575)

 

Inventories

 

(235)

   

192

 

Other current assets

 

(74)

   

165

 

Other assets

 

(23)

   

(138)

 

Accounts payable and claims and discounts payable

 

521

   

98

 

Accrued expenses

 

33

   

(401)

 

Other long-term liabilities

 

(30)

   

24

 

Net cash provided by operating activities

 

$

3,069

   

$

2,542

 

 

Adjusted Earnings Per Share
(Unaudited)

For internal comparisons, management finds it useful to assess year-over-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.

The Company defines adjusted earnings per share as income before income tax provision plus amortization, less adjusted income tax provision, divided by the weighted average diluted shares outstanding.

The following is a reconciliation of income before income tax provision to adjusted earnings per share:

   

ThreeMonthsEnded

June30,

 

Six MonthsEnded

June30,

Inmillions,exceptpershareamounts

 

2014

   

2013

   

2014

   

2013

 

Income before income tax provision

 

$

2,050

   

$

1,846

   

$

3,916

   

$

3,414

 

Amortization

 

133

   

124

   

264

   

246

 

Adjusted income before income tax provision

 

2,183

   

1,970

   

4,180

   

3,660

 

Adjusted income tax provision(1)

 

856

   

770

   

1,645

   

1,432

 

Adjusted net income

 

$

1,327

   

$

1,200

   

$

2,535

   

$

2,228

 
                         

Weighted average diluted shares outstanding

 

1,174

   

1,236

   

1,182

   

1,238

 

Adjusted earnings per share

 

$

1.13

   

$

0.97

   

$

2.15

   

$

1.80

 
                                 

(1) The adjusted income tax provision is computed using the effective income tax rate computed from the condensed consolidated statement of income.

 

Free Cash Flow
(Unaudited)

The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).

The following is a reconciliation of net cash provided by operating activities to free cash flow:

   

Six MonthsEnded

June30,

Inmillions

 

2014

   

2013

 
             

Net cash provided by operating activities

 

$

3,069

   

$

2,542

 

Subtract: Additions to property and equipment

 

(891)

   

(804)

 

Add: Proceeds from sale-leaseback transactions

 

5

   

 

 

Free cash flow

 

$

2,183

   

$

1,738

 

 

Supplemental Information
(Unaudited)

The Company evaluates its Pharmacy Services and Retail Pharmacy Segment performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements:

 

Inmillions

 

Pharmacy

Services

Segment(1)

 

Retail

Pharmacy

Segment

 

Corporate

Segment

 

Intersegment

Eliminations(2)

 

Consolidated

Totals

Three Months Ended

                             

June30, 2014:

                             

Net revenues

 

$

21,836

   

$

16,871

   

$

 

   

$

(4,105)

   

$

34,602

 

Gross profit

 

1,195

   

5,299

   

 

   

(170)

   

6,324

 

Operating profit (loss)

 

878

   

1,705

   

(205)

   

(170)

   

2,208

 

June30, 2013:

                             

Net revenues

 

18,800

   

16,139

   

 

   

(3,691)

   

31,248

 

Gross profit

 

963

   

5,005

   

 

   

(127)

   

5,841

 

Operating profit (loss)

 

675

   

1,600

   

(176)

   

(127)

   

1,972

 

Six Months Ended

                             

June30, 2014:

                             

Net revenues

 

42,031

   

33,351

   

 

   

(8,091)

   

67,291

 

Gross profit

 

2,129

   

10,483

   

 

   

(346)

   

12,266

 

Operating profit (loss)

 

1,518

   

3,455

   

(395)

   

(346)

   

4,232

 

June30, 2013:

                             

Net revenues

 

37,111

   

32,179

   

 

   

(7,291)

   

61,999

 

Gross profit

 

1,731

   

9,952

   

 

   

(265)

   

11,418

 

Operating profit (loss)

 

1,174

   

3,132

   

(375)

   

(265)

   

3,666

 

Total Assets:

                             

June 30, 2014

 

41,189

   

30,803

   

1,790

   

(1,189)

   

72,593

 

December 31, 2013

 

38,343

   

30,191

   

4,420

   

(1,428)

   

71,526

 

Goodwill:

                             

June 30, 2014

 

21,233

   

6,893

   

 

   

 

   

28,126

 

December 31, 2013

 

19,658

   

6,884

   

 

   

 

   

26,542

 
                               

(1) Net revenues of the Pharmacy Services Segment includes approximately $2.0 billion of retail co-payments for the three months ended both June 30, 2014 and 2013, as well as $4.2 billion of retail co-payments for the six months ended both June 30, 2014 and 2013.

                                         

(2) Intersegment eliminations relate to two types of transaction: (i) Intersegment revenues that occur when Pharmacy Services Segment customers use Retail Pharmacy Segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a stand-alone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services Segment customers, through the Company's intersegment activities (such as the Maintenance Choice program), elect to pick up their maintenance prescriptions at Retail Pharmacy Segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. The following amounts are eliminated in consolidation in connection with the intersegment activity described in item (ii) above: net revenues of $1.2 billion and $1.1 billion for the three months ended June 30, 2014 and 2013, respectively, and $2.3 billion and $2.0 billion for the six months ended June 30, 2014 and 2013, respectively; and gross profit and operating profit of $170 million and $127 million for the three months ended June 30, 2014 and 2013, respectively, and $346 million and $265 million for the six months ended June 30, 2014 and 2013, respectively.

 

Supplemental Information
(Unaudited)

Pharmacy Services Segment

The following table summarizes the Pharmacy Services Segment's performance for the respective periods:

   

ThreeMonthsEnded

June30,

 

Six MonthsEnded

June30,

Inmillions

 

2014

   

2013

   

2014

   

2013

 
                         

Net revenues

 

$

21,836

   

$

18,800

   

$

42,031

   

$

37,111

 

Gross profit

 

1,195

   

963

   

2,129

   

1,731

 

Gross profit % of net revenues

 

5.5

%

 

5.1

%

 

5.1

%

 

4.7

%

Operating expenses

 

317

   

288

   

611

   

557

 

Operating expense % of net revenues

 

1.5

%

 

1.5

%

 

1.5

%

 

1.5

%

Operating profit

 

878

   

675

   

1,518

   

1,174

 

Operating profit % of net revenues

 

4.0

%

 

3.6

%

 

3.6

%

 

3.2

%

Net revenues(1)(4):

                       

Mail choice(2)

 

$

7,753

   

$

6,036

   

$

14,587

   

$

11,905

 

Pharmacy network(3)

 

14,025

   

12,709

   

27,327

   

25,100

 

Other

 

58

   

55

   

117

   

105

 

Pharmacy claims processed(1):

                       

Total

 

230.9

   

226.6

   

458.7

   

454.3

 

Mail choice(2)

 

20.5

   

20.7

   

40.3

   

41.3

 

Pharmacy network(3)

 

210.4

   

205.9

   

418.4

   

413.0

 

Generic dispensing rate(1):

                       

Total

 

82.4

%

 

80.7

%

 

82.0

%

 

80.6

%

Mail choice(2)

 

74.6

%

 

75.8

%

 

72.5

%

 

75.6

%

Pharmacy network(3)

 

83.2

%

 

81.1

%

 

83.0

%

 

81.0

%

Mail choice penetration rate

 

21.6

%

 

22.4

%

 

21.4

%

 

22.3

%

                         

(1) Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within

the mail choice category.

 

(2) Mail choice is defined as claims filled at a Pharmacy Services mail facility, which include specialty mail claims, as well as 90-day claims filled at

retail under the Maintenance Choice program.

 

(3) Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores, but excluding Maintenance Choice activity.

 

(4) In May 2014, the Company implemented Specialty Connect, which integrates the Company's mail and retail capabilities, providing members with

the choice to bring their specialty prescriptions to any CVS/pharmacy location. Whether submitted through our mail order pharmacy or at

CVS/pharmacy, all prescriptions are filled through the Company's specialty mail order pharmacies, so all revenue from this specialty prescription

services program is recorded within the Pharmacy Services Segment. Members then can choose to pick up their medication at their local

CVS/pharmacy or have it sent to their home through the mail.

 

 

Supplemental Information
(Unaudited)

Retail Pharmacy Segment

The following table summarizes the Retail Pharmacy Segment's performance for the respective periods:

   

ThreeMonthsEnded

June30,

 

Six MonthsEnded

June30,

Inmillions

 

2014

   

2013

   

2014

   

2013

 
                         

Net revenues

 

$

16,871

   

$

16,139

   

$

33,351

   

$

32,179

 

Gross profit

 

5,299

   

5,005

   

10,483

   

9,952

 

Gross profit % of net revenues

 

31.4

%

 

31.0

%

 

31.4

%

 

30.9

%

Operating expenses

 

3,594

   

3,404

   

7,028

   

6,819

 

Operating expense % of net revenues

 

21.3

%

 

21.1

%

 

21.1

%

 

21.2

%

Operating profit

 

1,705

   

1,600

   

3,455

   

3,132

 

Operating profit % of net revenues

 

10.1

%

 

9.9

%

 

10.4

%

 

9.7

%

Retail prescriptions filled (90 Day = 3 Rx) (1)

 

230.3

   

219.7

   

457.4

   

440.1

 

Net revenue increase:

                       

Total

 

4.5

%

 

2.0

%

 

3.6

%

 

1.1

%

Pharmacy

 

5.4

%

 

2.4

%

 

4.8

%

 

0.6

%

Front store

 

1.1

%

 

1.1

%

 

(0.6)

%

 

2.1

%

Total prescription volume (90 Day = 3 Rx) (1)

 

4.8

%

 

5.9

%

 

3.8

%

 

5.7

%

Same store increase (decrease)(2):

                       

Total sales

 

3.3

%

 

0.5

%

 

2.4

%

 

(0.4)

%

Pharmacy sales

 

5.0

%

 

1.0

%

 

4.4

%

 

(0.8)

%

Front store sales

 

(0.4)

%

 

(0.4)

%

 

(2.1)

%

 

0.5

%

Prescription volume (90 Day = 3 Rx) (1)

 

3.9

%

 

5.0

%

 

3.0

%

 

4.8

%

Generic dispensing rate

 

83.5

%

 

81.9

%

 

83.2

%

 

81.6

%

Pharmacy % of total revenues

 

69.6

%

 

69.1

%

 

69.8

%

 

69.0

%

Third party % of pharmacy revenue

 

98.7

%

 

97.8

%

 

98.5

%

 

97.8

%

                                 

(1) Includes the adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these

prescriptions include approximately three times the amount of product days supplied compared to a normal 30-day prescription.

 

(2) Same store sales exclude revenues from MinuteClinic and stores in Brazil.

 

Adjusted Earnings Per Share Guidance
(Unaudited)

The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2013 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-over-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.

 

Inmillions,exceptpershareamounts

 

Year Ending

December31,2014

             

Income before income tax provision

 

$

8,041

   

$

8,178

 

Amortization

 

518

   

520

 

Adjusted income before income tax provision

 

8,559

   

8,698

 

Adjusted income tax provision

 

3,371

   

3,422

 

Adjusted income from continuing operations

 

$

5,188

   

$

5,276

 
             

Weighted average diluted shares outstanding

 

1,172

   

1,170

 

Adjusted earnings per share from continuing operations

 

$

4.43

   

$

4.51

 

 

Inmillions,exceptpershareamounts

 

Three Months Ending

September30,2014

             

Income before income tax provision

 

$

2,007

   

$

2,064

 

Amortization

 

125

   

127

 

Adjusted income before income tax provision

 

2,132

   

2,191

 

Adjusted income tax provision

 

841

   

863

 

Adjusted income from continuing operations

 

$

1,291

   

$

1,328

 
             

Weighted average diluted shares outstanding

 

1,168

   

1,167

 

Adjusted earnings per share from continuing operations

 

$

1.11

   

$

1.14

 

 

Free Cash Flow Guidance
(Unaudited)

The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2013 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-over-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions.

Inmillions

 

Year Ending

December31,2014

             

Net cash provided by operating activities

 

$

7,150

   

$

7,450

 

Subtract: Additions to property and equipment

 

(2,300)

   

(2,200)

 

Add: Proceeds from sale-leaseback transactions

 

600

   

500

 

Free cash flow

 

$

5,450

   

$

5,750

 

 

Logo - http://photos.prnewswire.com/prnh/20090226/NE75914LOGO

 

SOURCE CVS Caremark Corporation

Like what you just read?